TRT in the UK: Who Is It For, What Are the Risks and How Is Treatment Monitored?

Testosterone replacement therapy, often shortened to TRT, may be considered for a man with significant compatible symptoms and consistently low testosterone on correctly timed blood tests. It is not a treatment for a number alone, a routine response to ageing or a general performance and wellbeing enhancer.

In the UK, testosterone medicines are prescription-only. A safe decision follows diagnosis, investigation of the cause, discussion of fertility, prostate and blood safety checks, cardiovascular assessment and shared decision-making. Information on this page is educational; it is not an offer of a particular prescription.

Who might be considered for testosterone replacement?

A clinician may discuss treatment when all of the following broadly apply:

• there are compatible symptoms or signs, with sexual symptoms often being the most specific;
• total testosterone is consistently low on at least two properly collected morning tests;
• SHBG and calculated free testosterone have been considered when relevant;
• reversible or alternative causes have been assessed;
• the expected benefits are meaningful to the individual;
• contraindications and important risks have been reviewed; and
• fertility is not currently being sought.

The lower the baseline testosterone and the clearer the symptoms, the more plausible a treatment benefit becomes. Men with a normal testosterone level are unlikely to gain the intended medical benefit and remain exposed to adverse effects.

What should happen before treatment is considered?

Confirm the diagnosis

The usual starting point is fasting total testosterone between about 7am and 10am. A low result is repeated on a different morning. LH and FSH help identify whether the cause is primarily testicular or related to pituitary or hypothalamic signalling. Prolactin and other tests are used selectively.

Look for reversible contributors

Obesity, poor sleep, sleep apnoea, acute or chronic illness, diabetes, heavy alcohol use and some medicines can reduce testosterone or cause similar symptoms. Treating these may improve health and sometimes testosterone without replacement.

Discuss fertility

External testosterone suppresses the hormonal signals that support sperm production. Sperm count may fall substantially and fertility can be impaired. A man who wants to conceive now must not be treated with testosterone as a substitute for fertility care. Men who may want children later should discuss this before starting.

Establish safety baselines

The clinician may assess:

• full blood count and haematocrit;
• blood pressure and cardiovascular risk;
• symptoms of sleep apnoea;
• urinary symptoms;
• prostate risk and PSA when appropriate;
• breast or prostate cancer history;
• heart failure and previous cardiovascular events; and
• personal or family history of blood clots.

Further assessment or specialist advice may be needed when risks are uncertain.

What benefits are realistic?

In appropriately selected men with confirmed hypogonadism, treatment may improve sexual desire and other sexual symptoms. It may also improve body composition, anaemia or bone density in some men.

Energy, mood and concentration are less specific outcomes. They may improve when testosterone deficiency is truly contributing, but no clinician can promise this. Treatment should have agreed goals so that lack of meaningful benefit can be recognised rather than continuing indefinitely by default.

What are the important risks and limitations?

Raised haematocrit

Testosterone can increase red blood-cell concentration. A high haematocrit increases concern about circulatory complications and requires action. A value above 54% is a recognised threshold for prompt review, adjustment or withdrawal of treatment and assessment of contributing factors.

Reduced fertility and testicular volume

Suppression of LH and FSH can reduce sperm production and testicular volume. Recovery after stopping may take time and is not guaranteed to follow a predictable timetable.

Skin, breast and fluid effects

Acne, oily skin, breast tenderness or enlargement and fluid retention can occur. The significance depends on severity and the man’s underlying health.

Sleep and urinary symptoms

Untreated severe sleep apnoea and severe lower urinary tract symptoms require careful assessment. Worsening symptoms should not simply be attributed to ageing.

Prostate monitoring

Current evidence does not show that properly prescribed replacement causes prostate cancer, but treatment can alter PSA and is not appropriate with active or advanced prostate cancer. Age- and risk-appropriate prostate assessment and follow-up are important.

Cardiovascular uncertainty

Cardiovascular risk should be assessed before treatment. Current guideline reviews have not shown a substantial rise in major cardiovascular events when testosterone is used to restore confirmed deficiency into the normal range, but long-term evidence is not perfect. Men with recent or unstable cardiovascular disease, uncontrolled heart failure or significant thrombosis risk need particular caution and sometimes specialist input.

Who should not start TRT?

Important contraindications include:

• active prostate cancer or male breast cancer;
• a current desire for fertility;
• haematocrit at or above 54%; and
• uncontrolled or poorly controlled heart failure.

Severe urinary symptoms, untreated severe sleep apnoea, high baseline haematocrit, recent cardiovascular events or a history of venous thrombosis can also alter the decision. This is not an exhaustive self-screening list.

How is treatment monitored?

A typical guideline-based framework is:

Men at higher risk may need more frequent review. The aim is not merely to keep a laboratory value inside a range; it is to confirm useful clinical benefit without unacceptable harm.

What if I do not feel better?

The clinician should check the diagnosis, adherence, treatment level, adverse effects and other possible causes of the symptoms. If testosterone has normalised but there is no meaningful improvement after a reasonable review period, continuing treatment may not be justified.

Never increase a dose or combine prescribed and non-prescribed hormones without clinical advice.